GHRP-2
← Back to LibraryCompound Profile
GHRP-2 is reviewed here for growth-hormone signaling and recovery context.
Research Summary
Safety notices, literature searches, limited protocol data
Growth-hormone signaling, Recovery, Body composition
Target context: GHS-R1a
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
100mcg
Dosing window
Pre-Bed Fasted
Receptor / target
GHS-R1a
Properties
GH Secretagogue
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100mcg 1x Daily | Administered pre-bed, completely fasted. |
| Weeks 3-4 | 150mcg 1x Daily | Administered pre-bed, completely fasted. |
| Weeks 5-8 | 200mcg 1x Daily | Administered pre-bed, completely fasted. |
| Weeks 9-12 | 250-300mcg 1x Daily | Administered pre-bed, completely fasted. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative 1: High Frequency
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg 3x daily | Morning, Post-Workout, Pre-Bed. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative 2: Anti-Aging Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 150mcg 1x Daily | Take at bedtime. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied around pituitary GH signaling, IGF-1 response, body-composition endpoints, growth-hormone deficiency models, or discontinued anabolic programs depending on the compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: GHS-R1a. Route(s): Subcutaneous. Dosing window on page: Pre-Bed Fasted. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- GH-axis compounds are best interpreted through pituitary physiology, IGF-1 response, pulse timing, and metabolic adverse effects rather than dose escalation alone.
- Evidence strength ranges from approved labels for specific agents to sparse or discontinued development programs for research peptides.
- FDA lists injectable/nasal GHRP-2 in category 2 with immunogenicity/impurity concerns and serious adverse event reports.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-2, 100mcg 1x Daily; Alternative 1: High Frequency: Weeks 1-12, 100mcg 3x daily.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor IGF-1 response, fasting glucose/A1c, edema, carpal-tunnel symptoms, blood pressure, sleep apnea, and malignancy history.
Selected medical sources
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active malignancy: GH/IGF-1 elevation may accelerate tumor cell proliferation.
- History of pituitary tumor or pituitary adenoma: unpredictable response to GHS-R1a stimulation.
- Uncontrolled diabetes mellitus or severe insulin resistance: GH elevation worsens glycemic control.
- Diabetic ketoacidosis.
- Active or history of prolactinoma: GHRP-2 elevates prolactin via GHS-R1a activation on lactotrophs.
- Hypersensitivity or known allergy to GHRP-2 or excipients.
- Concurrent use with ipamorelin or GHRP-6: receptor competition at GHS-R1a; do not stack two GHRPs.
- Concurrent use with HGH 191aa: additive and redundant GH axis overstimulation.
- Concomitant high-dose glucocorticoid therapy: attenuates pituitary GH response and amplifies cortisol load from GHRP stimulation.
- Concomitant insulin therapy without adjustment: GH-mediated insulin resistance may destabilize glycemic control.
- High baseline cortisol or adrenal stress states: GHRP-2's cortisol-elevating effect adds further HPA axis load.
- Pregnancy: safety not established.
- Breastfeeding: safety not established.
- Pediatric use with closed growth plates.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Acute hunger and appetite stimulation: moderate; centrally mediated via ghrelin pathway NPY/AgRP activation; less intense than GHRP-6 but more than ipamorelin; begins within 20-30 minutes of injection.
- Mild cortisol elevation: transient, typically returns to baseline within 2-4 hours post-injection; approximately 40% less than GHRP-6 at equipotent doses; monitor in subjects with baseline cortisol concerns.
- Mild prolactin elevation: transient; similar pattern to cortisol response; lower than GHRP-6 and hexarelin.
- Head rush and transient facial flushing: acute vasodilation from GH pulse; resolves within 15-30 minutes.
- Water retention and peripheral edema: GH-mediated sodium and fluid retention; common in first 2-4 weeks.
- Joint stiffness: GH-related periarticular fluid accumulation.
- Tingling or numbness in extremities: paresthesia; GH-related fluid shifts.
- Vivid dreams: GH elevation during nocturnal sleep.
- Lethargy and mild fatigue post-injection: associated with the acute GH pulse.
- Headache: vasodilation-related; typically early in the protocol.
- Injection site irritation: redness, swelling, or pain at subcutaneous administration site.
- Mild transient hypoglycemia: possible when dosing fasted, particularly with GHRH analog co-administration.
- Insulin resistance: with extended high-dose protocols; GH elevation progressively reduces insulin sensitivity; monitor fasting glucose.
- Decreased efficacy of corticosteroid therapy: GHRP-2 can blunt glucocorticoid response.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: